214 related articles for article (PubMed ID: 31932214)
1. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
[TBL] [Abstract][Full Text] [Related]
3. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
[TBL] [Abstract][Full Text] [Related]
4. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
[TBL] [Abstract][Full Text] [Related]
5. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
McAndrew EN; Zhang H; Lambert P; Rittberg R; Dawe DE; Kim CA
Am J Clin Oncol; 2022 Feb; 45(2):55-60. PubMed ID: 35073280
[TBL] [Abstract][Full Text] [Related]
9. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
[TBL] [Abstract][Full Text] [Related]
10. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
11. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Ramanathan RK; McDonough SL; Philip PA; Hingorani SR; Lacy J; Kortmansky JS; Thumar J; Chiorean EG; Shields AF; Behl D; Mehan PT; Gaur R; Seery T; Guthrie KA; Hochster HS
J Clin Oncol; 2019 May; 37(13):1062-1069. PubMed ID: 30817250
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG; Boone BA; Chau I; Clarke S; Dillhoff M; El-Rayes BF; Frakes JM; Grose D; Hosein PJ; Jamieson NB; Javed AA; Khan K; Kim KP; Kim SC; Kim SS; Ko AH; Lacy J; Margonis GA; McCarter MD; McKay CJ; Mellon EA; Moorcraft SY; Okada KI; Paniccia A; Parikh PJ; Peters NA; Rabl H; Samra J; Tinchon C; van Tienhoven G; van Veldhuisen E; Wang-Gillam A; Weiss MJ; Wilmink JW; Yamaue H; Homs MYV; van Eijck CHJ; Katz MHG; Groot Koerkamp B
J Natl Cancer Inst; 2019 Aug; 111(8):782-794. PubMed ID: 31086963
[TBL] [Abstract][Full Text] [Related]
13. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
14. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
[TBL] [Abstract][Full Text] [Related]
17. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G
Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
[TBL] [Abstract][Full Text] [Related]
19. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
[TBL] [Abstract][Full Text] [Related]
20. Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Caron B; Reimund JM; Ben Abdelghani M; Sondag D; Noirclerc M; Duclos B; Kurtz JE; Nguimpi-Tambou M
Pancreas; 2021 Jul; 50(6):803-806. PubMed ID: 34347737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
